化疗联合中药序贯口服治疗晚期非小细胞肺癌的临床研究
|
摘要
目的:观察化疗联合中药序贯口服治疗晚期非小细胞肺癌的临床疗效。方法:将经影像学及病理或细胞学确诊为晚期非小细胞肺癌患者41例,随机分为治疗组和对照组,治疗组20例,对照组21例,对照组予PC或TC方案化疗,治疗组予PC或TC方案化疗加中药序贯口服,化疗4周期后观察两组在中医证候、临床受益率、全身状态和免疫指标等方面的差别,评价两组临床疗效。结果:治疗组临床症状改善总有效率90%,对照组临床症状改善总有效率60%,差异有统计学意义(P<0.05);治疗组临床受益率90%,对照组临床受益率60%,差异有统计学意义(P<0.05);治疗组治疗后免疫指标变化总有效率80%,对照组治疗后免疫指标变化总有效率50%,差异有统计学意义(P<0.05);治疗组治疗后全身状态变化总有效率90%,对照组治疗后全身状态变化总有效率45%,差异有统计学意义(P<0.05)。结论:化疗联合中药序贯口服在治疗晚期非小细胞肺癌方面疗效确切,具有临床推广意义。
Objective: To observe the curative effects of chemotherapy combined with sequential therapy of Chinese medication in the treatment of non-small cell lung cancer(NSCLC) of advanced stage. Methods: A total of 41 patients diagnosed with NSCLC by imaging and pathological or cytological method were randomly divided into the control group(n=21) and the treatment group(n=20). The control group was intervened with PC or TC chemotherapy plan; on which basis, the treatment group was also intervened with sequential therapy of Chinese medication. After four weeks of chemotherapy, the differences in TCM syndrome, clinical effect, general body state, and immune indexes were compared between the two groups. Results: The total effective rate of improving clinical symptoms was 90% in the treatment group, which was significantly higher than 60% in the control group(P<0.05). The clinical benefit rate was 90% in the treatment group, which was significantly higher than 65% in the control group(P<0.05). The total effective rate of immune indexes was 80% in the treatment group, which was greatly higher than 50% in the control group(P<0.05). The total effective rate of general body state was 90% in the treatment group, which was greatly higher than 45% in the control group(P<0.05). Conclusion: There is a remarkable curative effect of chemotherapy combined with sequential therapy of Chinese medication in the treatment of NSCLC of advanced stage, which is worthy of clinical promotion.
Objective: To observe the curative effects of chemotherapy combined with sequential therapy of Chinese medication in the treatment of non-small cell lung cancer(NSCLC) of advanced stage. Methods: A total of 41 patients diagnosed with NSCLC by imaging and pathological or cytological method were randomly divided into the control group(n=21) and the treatment group(n=20). The control group was intervened with PC or TC chemotherapy plan; on which basis, the treatment group was also intervened with sequential therapy of Chinese medication. After four weeks of chemotherapy, the differences in TCM syndrome, clinical effect, general body state, and immune indexes were compared between the two groups. Results: The total effective rate of improving clinical symptoms was 90% in the treatment group, which was significantly higher than 60% in the control group(P<0.05). The clinical benefit rate was 90% in the treatment group, which was significantly higher than 65% in the control group(P<0.05). The total effective rate of immune indexes was 80% in the treatment group, which was greatly higher than 50% in the control group(P<0.05). The total effective rate of general body state was 90% in the treatment group, which was greatly higher than 45% in the control group(P<0.05). Conclusion: There is a remarkable curative effect of chemotherapy combined with sequential therapy of Chinese medication in the treatment of NSCLC of advanced stage, which is worthy of clinical promotion.
引文
[1] 陈万青,孙可欣,郑荣寿,等.2014年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤,2018,27(1):1-14.
[2] 武乐,刘震天,叶华姝.厄洛替尼与吉非替尼治疗非小细胞肺癌的疗效与经济优势对比[J].中国医学创新,2018,15(32):135-138.
[3] 宋燕,陈金华,付曦.不同化疗方案治疗老年晚期非小细胞肺癌的效果观察[J].解放军医药杂志,2018,30(8):25-28.
[4] 万涛,熊伟杰,崔丹丹.晚期非小细胞肺癌化疗方案成本-效果比较[J].现代仪器与医疗,2017,23(4):44-46.
[5] 王呈祥,李庆伟,高彦宇,等.中医药联合现代医学治疗非小细胞肺癌研究进展[J].中医药信息,2017,34(1):121-123.
[6] 容国义,王淑美,唐末.中医化痰法治疗非小细胞肺癌疗效的Meta分析[J].中国临床药理学与治疗学,2017,22(7):787-794.
[7] 张俊红,王镓,崔青荣.金复康口服液对气阴两虚型非小细胞肺癌患者的疗效和血清MMP-9水平的影响[J].中医药信息,2019,36(2):65-68.
[8] 孟晓,韩燕,徐咏梅,等.180例晚期非小细胞肺癌患者中医证候分布与组合规律[J].中华中医药杂志,2014,29(9):2978-2982.
[9] 王天翔,魏希强,孙伟.洛铂联用多西他赛与顺铂联用多西他赛治疗晚期非小细胞肺癌疗效与安全性对比[J].现代仪器与医疗,2016,22(3):111-112+62.
[10] 高广毅.扶正抗癌方治疗晚期非小细胞肺癌疗效的Meta分析[J].实用癌症杂志,2017,32(5):789-792.
[11] 李慧杰,齐元富,李秀荣.基于癌毒理论探讨攻毒治法抗肿瘤转移[J].中医药信息,2018,35(4):81-83.
[12] 梁芳,张勇,李朝衡,等.益气养阴解毒方对非小细胞肺癌患者T细胞亚群及Thl/Th2漂移的影响[J].实用中医内科杂志,2011,25(5):8-10.
[13] 王宁,唐广义,殷东风.益气健脾抗癌法对肠癌脾虚本质的影响及抗肿瘤作用实验研究[J].辽宁中医杂志,2014,41(5):1054-1057.
[14] 罗建江,李向林.干蟾皮醇提物对A549和NCI-H460肺癌细胞活性的影响[J].上海中医药大学学报,2016,30(4):57-60.
[15] 姚娓,刘艳红,张红,等.蜂房提取物抑制H22小鼠移植瘤增殖的作用研究[J].肿瘤学杂志,2012,18(4):270-273.
[2] 武乐,刘震天,叶华姝.厄洛替尼与吉非替尼治疗非小细胞肺癌的疗效与经济优势对比[J].中国医学创新,2018,15(32):135-138.
[3] 宋燕,陈金华,付曦.不同化疗方案治疗老年晚期非小细胞肺癌的效果观察[J].解放军医药杂志,2018,30(8):25-28.
[4] 万涛,熊伟杰,崔丹丹.晚期非小细胞肺癌化疗方案成本-效果比较[J].现代仪器与医疗,2017,23(4):44-46.
[5] 王呈祥,李庆伟,高彦宇,等.中医药联合现代医学治疗非小细胞肺癌研究进展[J].中医药信息,2017,34(1):121-123.
[6] 容国义,王淑美,唐末.中医化痰法治疗非小细胞肺癌疗效的Meta分析[J].中国临床药理学与治疗学,2017,22(7):787-794.
[7] 张俊红,王镓,崔青荣.金复康口服液对气阴两虚型非小细胞肺癌患者的疗效和血清MMP-9水平的影响[J].中医药信息,2019,36(2):65-68.
[8] 孟晓,韩燕,徐咏梅,等.180例晚期非小细胞肺癌患者中医证候分布与组合规律[J].中华中医药杂志,2014,29(9):2978-2982.
[9] 王天翔,魏希强,孙伟.洛铂联用多西他赛与顺铂联用多西他赛治疗晚期非小细胞肺癌疗效与安全性对比[J].现代仪器与医疗,2016,22(3):111-112+62.
[10] 高广毅.扶正抗癌方治疗晚期非小细胞肺癌疗效的Meta分析[J].实用癌症杂志,2017,32(5):789-792.
[11] 李慧杰,齐元富,李秀荣.基于癌毒理论探讨攻毒治法抗肿瘤转移[J].中医药信息,2018,35(4):81-83.
[12] 梁芳,张勇,李朝衡,等.益气养阴解毒方对非小细胞肺癌患者T细胞亚群及Thl/Th2漂移的影响[J].实用中医内科杂志,2011,25(5):8-10.
[13] 王宁,唐广义,殷东风.益气健脾抗癌法对肠癌脾虚本质的影响及抗肿瘤作用实验研究[J].辽宁中医杂志,2014,41(5):1054-1057.
[14] 罗建江,李向林.干蟾皮醇提物对A549和NCI-H460肺癌细胞活性的影响[J].上海中医药大学学报,2016,30(4):57-60.
[15] 姚娓,刘艳红,张红,等.蜂房提取物抑制H22小鼠移植瘤增殖的作用研究[J].肿瘤学杂志,2012,18(4):270-273.